Eugenia L Kim, DO | |
874 Proprietors Rd, Worthington, OH 43085-3152 | |
(614) 885-9405 | |
(614) 885-9481 |
Full Name | Eugenia L Kim |
---|---|
Gender | Female |
Speciality | Family Practice |
Experience | 14 Years |
Location | 874 Proprietors Rd, Worthington, Ohio |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1063732956 | NPI | - | NPPES |
0086760 | Medicaid | OH |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | 34.010926 (Ohio) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Ohiohealth Home Health | Worthington, OH | Home health agency |
Riverside Methodist Hospital | Columbus, OH | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Central Ohio Primary Care Physicians, Inc. | 2769383785 | 488 |
News Archive
Researchers report in the journal Cell Reports a targeted molecular therapy that dramatically reduces the initial development of Non Alcoholic Fatty Liver Disease (NAFLD) in laboratory mouse models of the disease.
This week's issue of the Journal of the American Medical Association (Dec 16) features a report on a long-term, prospective study of elderly, dementia-free individuals led by researchers from Boston University School of Medicine and the Framingham Heart Study focusing on the association between the protein hormone Leptin and the risk of developing Alzheimer's disease (AD).
The need for psychiatric services in inpatient hospitals continues to grow, according to the latest annual survey from the National Association of Psychiatric Health Systems released today. The survey reports 2012 data that was collected in 2013 from NAPHS-member organizations. Data were analyzed and reported by Dobson DaVanzo & Associates, LLC, Vienna, VA.
MEI Pharma, Inc., an oncology company focused on the clinical development of novel therapies for cancer, announced today that the first patient has been dosed in a Phase Ib clinical study of its investigational mitochondrial inhibitor drug candidate ME-344 in combination with Hycamtin (topotecan) in patients with solid tumors, including small cell lung and ovarian cancers.
However, it cannot be confirmed for certain that the strain has been eliminated, raising the question of how long a strain must go undetected before being considered, in all probability, extinct.
› Verified 8 days ago
Entity Name | Ohiohealth Corporation |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1578545273 PECOS PAC ID: 6305758426 Enrollment ID: O20031105000532 |
News Archive
Researchers report in the journal Cell Reports a targeted molecular therapy that dramatically reduces the initial development of Non Alcoholic Fatty Liver Disease (NAFLD) in laboratory mouse models of the disease.
This week's issue of the Journal of the American Medical Association (Dec 16) features a report on a long-term, prospective study of elderly, dementia-free individuals led by researchers from Boston University School of Medicine and the Framingham Heart Study focusing on the association between the protein hormone Leptin and the risk of developing Alzheimer's disease (AD).
The need for psychiatric services in inpatient hospitals continues to grow, according to the latest annual survey from the National Association of Psychiatric Health Systems released today. The survey reports 2012 data that was collected in 2013 from NAPHS-member organizations. Data were analyzed and reported by Dobson DaVanzo & Associates, LLC, Vienna, VA.
MEI Pharma, Inc., an oncology company focused on the clinical development of novel therapies for cancer, announced today that the first patient has been dosed in a Phase Ib clinical study of its investigational mitochondrial inhibitor drug candidate ME-344 in combination with Hycamtin (topotecan) in patients with solid tumors, including small cell lung and ovarian cancers.
However, it cannot be confirmed for certain that the strain has been eliminated, raising the question of how long a strain must go undetected before being considered, in all probability, extinct.
› Verified 8 days ago
Entity Name | Central Ohio Primary Care Physicians, Inc. |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1194705194 PECOS PAC ID: 2769383785 Enrollment ID: O20040114000204 |
News Archive
Researchers report in the journal Cell Reports a targeted molecular therapy that dramatically reduces the initial development of Non Alcoholic Fatty Liver Disease (NAFLD) in laboratory mouse models of the disease.
This week's issue of the Journal of the American Medical Association (Dec 16) features a report on a long-term, prospective study of elderly, dementia-free individuals led by researchers from Boston University School of Medicine and the Framingham Heart Study focusing on the association between the protein hormone Leptin and the risk of developing Alzheimer's disease (AD).
The need for psychiatric services in inpatient hospitals continues to grow, according to the latest annual survey from the National Association of Psychiatric Health Systems released today. The survey reports 2012 data that was collected in 2013 from NAPHS-member organizations. Data were analyzed and reported by Dobson DaVanzo & Associates, LLC, Vienna, VA.
MEI Pharma, Inc., an oncology company focused on the clinical development of novel therapies for cancer, announced today that the first patient has been dosed in a Phase Ib clinical study of its investigational mitochondrial inhibitor drug candidate ME-344 in combination with Hycamtin (topotecan) in patients with solid tumors, including small cell lung and ovarian cancers.
However, it cannot be confirmed for certain that the strain has been eliminated, raising the question of how long a strain must go undetected before being considered, in all probability, extinct.
› Verified 8 days ago
Mailing Address | Practice Location Address |
---|---|
Eugenia L Kim, DO 874 Proprietors Rd, Worthington, OH 43085-3152 Ph: (614) 885-9405 | Eugenia L Kim, DO 874 Proprietors Rd, Worthington, OH 43085-3152 Ph: (614) 885-9405 |
News Archive
Researchers report in the journal Cell Reports a targeted molecular therapy that dramatically reduces the initial development of Non Alcoholic Fatty Liver Disease (NAFLD) in laboratory mouse models of the disease.
This week's issue of the Journal of the American Medical Association (Dec 16) features a report on a long-term, prospective study of elderly, dementia-free individuals led by researchers from Boston University School of Medicine and the Framingham Heart Study focusing on the association between the protein hormone Leptin and the risk of developing Alzheimer's disease (AD).
The need for psychiatric services in inpatient hospitals continues to grow, according to the latest annual survey from the National Association of Psychiatric Health Systems released today. The survey reports 2012 data that was collected in 2013 from NAPHS-member organizations. Data were analyzed and reported by Dobson DaVanzo & Associates, LLC, Vienna, VA.
MEI Pharma, Inc., an oncology company focused on the clinical development of novel therapies for cancer, announced today that the first patient has been dosed in a Phase Ib clinical study of its investigational mitochondrial inhibitor drug candidate ME-344 in combination with Hycamtin (topotecan) in patients with solid tumors, including small cell lung and ovarian cancers.
However, it cannot be confirmed for certain that the strain has been eliminated, raising the question of how long a strain must go undetected before being considered, in all probability, extinct.
› Verified 8 days ago
Dr. Jeffrey L Hunter, D.O. Family Medicine Medicare: Medicare Enrolled Practice Location: 445 E Granville Rd, Worthington, OH 43085 Phone: 614-293-2850 | |
Veronique Bartman, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 160 W Wilson Bridge Rd, Worthington, OH 43085 Phone: 614-293-2850 Fax: 614-293-2849 | |
Scott Michael Reineck, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 874 Proprietors Rd, Worthington, OH 43085 Phone: 614-885-9405 Fax: 614-885-9481 | |
Dr. Harkiran Singh, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 160 W Wilson Bridge Rd, Worthington, OH 43085 Phone: 614-293-2850 Fax: 614-293-2849 | |
Elizabeth S Unk, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 874 Proprietors Rd, Worthington, OH 43085 Phone: 614-885-9405 Fax: 614-885-9481 | |
John M Jonesco, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 445 E Dublin Granville Rd, Worthington, OH 43085 Phone: 614-293-2850 Fax: 614-293-2849 |